Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma
Cancer Medicine ( IF 2.9 ) Pub Date : 2022-12-01 , DOI: 10.1002/cam4.5460
Sehhoon Park ₁ , Hongui Cha _{2,

3} , Hong Sook Kim ₂ , Boram Lee _{2,

3} , Soyeon Kim _{4,

5} , Tae Min Kim _{4,

6} , Hyu Ae Jung ₁ , Jong-Mu Sun ₁ , Jin Seok Ahn ₁ , Myung-Ju Ahn ₁ , Keunchil Park _{1,

2} , Woong-Yang Park _{2,

3} , Se-Hoon Lee _{1,

2}

Affiliation

The chemokine CXCL13 is known to influence local anti-tumor immunity by recruiting immune cells and forming tertiary lymphoid structures (TLS). It has been hypothesized that TLS, led by the expression of CXCL13, could be a predictive or prognostic biomarker for immunotherapy. We investigated the predictive value of CXCL13 to immune checkpoint inhibitors (ICI) in lung adenocarcinoma.

中文翻译：

CXCL13 的转录上调与肺腺癌对免疫检查点抑制剂的良好反应相关

已知趋化因子CXCL13通过募集免疫细胞和形成三级淋巴结构 (TLS) 来影响局部抗肿瘤免疫。据推测，由CXCL13的表达引导的 TLS可能是免疫疗法的预测或预后生物标志物。我们调查了CXCL13对免疫检查点抑制剂 (ICI) 在肺腺癌中的预测价值。

更新日期：2022-12-01

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南